The recent change in @CDCgov policy regarding masking has prompted a lot of people to ask: do #COVID19#vaccines block transmission of the virus to others? Here is a 🧵using slides my colleagues and I put together recently. @DrJRMarcelin@ElizabethRBrow2
Slides made by me (Harvard), Audrey Pettifor (UNC), Jasmine Marcelin (UNMC), and Holly Janes and Elizabeth Brown at the Hutch.
It seems like there is new data every day, so apologies if our slides are already missing something. But here is a summary of some good observational studies on the topic.
Same with the trial data - constantly evolving. Here's a sample. VE means vaccine efficacy
This question comes up a lot - a little data showing that asymptomatic infections can have a decent amount of viral shedding
Might be simple for some, but it helps to remember how easily observational studies can be misinterpreted
Another common mistake in observational studies
Measuring viral kinetics is extremely challenging - the frequency of testing is a huge factor in accuracy
This is may be the most relevant point recently. We still don't know very much about transmission events following breakthrough infections.
How is this all relevant to the masking policies? The point here is that we know that vaccines block asymptomatic infection, at least partially. But we don't know a lot about how much forward transmission can occur in the setting of breakthrough infections.
This data may not always be so important! If everyone is vaccinated, then it's not a big deal. We're all protected against symptomatic disease. And if there's extremely low amounts of virus circulating, it also may not be a big deal.
When this data really matters is when there is partial vaccination and moderate amounts of circulating virus. That's when we really need to accurately understand the risk of transmission following breakthrough infections. And we don't have that data yet.
This study reminds me of the above limitation. They looked at incidence rates among non-vaccinated pts at the same time that general incidence rates were dropping. Of course vaccines are amazing, but not sure how robust the findings are here.@walidgellad nytimes.com/2021/05/19/hea…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We enrolled 36 people with SARS-CoV-2 (11 on Paxlovid) and did PCR every day for 2+ weeks. Here’s what we found… (1/8) medrxiv.org/content/10.110…
One person out of 25 in the untreated group had viral rebound (4%), defined as at least 2 negative PCRs followed by at least 2 positives. 3 people out of 11 who took Paxlovid had rebound (27%). Those that rebounded after Paxlovid looked similar to an acute infection (2/8)
(abrupt rise to a high level of virus, with 6-12 days to clear). The single case of viral rebound without treatment was more like a viral “blip.”
For people who didn’t rebound, Paxlovid significantly reduced the # of days positive – from 7 days to 3.5 days. But when (3/8)
I gave a talk this morning about #Omicron with @PaulSaxMD@SanjatKanjilal & Dr. Ruanne Barnabas. We covered a lot of science but our bottom line was always the same: we need to increase access to diagnostics, treatments & vaccines to truly control COVID-19. 🧵and slides... 1/10
It's only been a year since we rolled out our vaccines, but since then we have administered >10 billion doses and probably prevented >1 million deaths in US alone. But inequity in global vaccination persists. 2/10
Omicron has created a challenge for our vaccines because of mutations in its spike protein, and this has led to reduced neutralizing antibody activity following a primary vaccine series. This has translated to increased breakthrough infections in real world studies. 3/10
Obviously it's good news that J&J vaccine is holding up against delta in data from South Africa. But the only reason we have that data is bc some insanely resourceful scientist heroes in SA scratched out 500K doses from thin air to protect their health care workers when ..
there were no COVID-19 vaccines in the entire country. Now we sit back in the US and watch delta surges burn through country after country and just lap up the data to help reassure us about the doses we already got! What's amazing about this study, what we really
should be talking about is how @LindaGailBekker Glenda Gray @nigegarrett had the guts to leverage research to vaccinate a half million health care workers who are now out there, protected, fighting to save countless unvaccinated South Africans through an incredibly chaotic time,
We just released data on the durability of immune responses following the J&J #COVID19#vaccine, including responses against #delta. The paper is in press @NEJM and this is the pre-print. To help explain the data, here’s a 🧵... 1/12 medrxiv.org/content/10.110…
Dan Barouch, myself and partners started running a 25 person study @BIDMC_CVVRTrial in July 2020 as part of the phase 1 J&J vaccine program. The study tests 1 dose vs. 2 doses (as well as high doses) against placebo. This study looks at immune responses – not efficacy. 2/12
First, a look back to some earlier data. Something not appreciated by general public from early data – there is no difference in immune responses between 1 vs. 2 doses at almost any time point we looked at. Importantly, this is when boost is given 2 months after first shot. 3/12
two types of vaccines. First there are 'pandemic' vaccines, which is what we have now - excellent at preventing hospitalizations and deaths and most useful for decompressing our health care infrastructure and reducing mortality in the most vulnerable. These vaccines will ... 2/5
have the biggest impact on returning to normal, so to speak, where schools, restaurants and workplaces can open up again. The second type of vaccines are 'maintenance' vaccines which are going to come as boosters or 2.0 versions optimized for new variants....3/5
Hi friends! Today's news about the NIH-Moderna #COVID19#vaccine is astonishingly good. I've never seen my colleagues - weathered, skeptical professor types - so giddy and delighted and surprised. Here's a thread about what it means (and doesn't): 🧵 1/n
There are caveats and I will get to them (wear a mask!), but for a moment let's look at the amazing numbers they reported: there were 95 cases of COVID-19 so far and *90* of those cases were in the group that got the fake (placebo) group. Only 5 cases were in the vaccine ... 2/14
group. The vaccine also seemed to protect against severe disease. There were 11 cases of severe COVID-19 in the placebo group and 0 cases in the vaccine group. 🤩 Wow!
So now, other things to know: ... 3/14